Literature DB >> 3546156

Ofloxacin: therapeutic results in Chlamydia trachomatis urethritis.

W Bischoff.   

Abstract

Sexually transmitted Chlamydia trachomatis infection of the genito-urinary tract is becoming recognized as a disease which has reached a higher incidence than gonococcal infections, and caused severe and complicated infections in males and females even without major complaints. The MicroTrak test is used to demonstrate C. trachomatis by direct identification under the fluorescence microscope using fluorescein-labelled monoclonal antibodies. 20 patients (15 males, five females) with proven C. trachomatis urethritis were treated for five days with 2 X 200 mg ofloxacin. The initial cure rate was 90% (18 of 20 patients) with an additional 10% being cured after extended therapy over ten days. No side-effects occurred during ofloxacin therapy. Thus ofloxacin can be regarded as an effective and safe drug for the treatment of the genito-urinary infections caused by C. trachomatis.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3546156     DOI: 10.1007/BF01661306

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  3 in total

1.  Monoclonal antibodies for diagnosis of infectious diseases in humans.

Authors:  R C Nowinski; M R Tam; L C Goldstein; L Stong; C C Kuo; L Corey; W E Stamm; H H Handsfield; J S Knapp; K K Holmes
Journal:  Science       Date:  1983-02-11       Impact factor: 47.728

2.  [Current status of infectious gynecologic diseases with special reference to sexually transmitted diseases].

Authors:  E Hochuli
Journal:  Ther Umsch       Date:  1984-07

3.  Monoclonal antibodies to Chlamydia trachomatis: antibody specificities and antigen characterization.

Authors:  R S Stephens; M R Tam; C C Kuo; R C Nowinski
Journal:  J Immunol       Date:  1982-03       Impact factor: 5.422

  3 in total
  6 in total

Review 1.  Treatment of genitourinary tract infections with fluoroquinolones: clinical efficacy in genital infections and adverse effects.

Authors:  D C Hooper; J S Wolfson
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

Review 2.  Ofloxacin. A reappraisal of its antimicrobial activity, pharmacology and therapeutic use.

Authors:  P A Todd; D Faulds
Journal:  Drugs       Date:  1991-11       Impact factor: 9.546

3.  Protective effects of sparfloxacin in experimental pneumonia caused by Chlamydia pneumoniae in leukopenic mice.

Authors:  K Nakata; Y Okazaki; H Hattori; S Nakamura
Journal:  Antimicrob Agents Chemother       Date:  1994-08       Impact factor: 5.191

4.  In vitro activities of T-3262, NY-198, fleroxacin (AM-833; RO 23-6240), and other new quinolone agents against clinically isolated Chlamydia trachomatis strains.

Authors:  H Maeda; A Fujii; K Nakata; S Arakawa; S Kamidono
Journal:  Antimicrob Agents Chemother       Date:  1988-07       Impact factor: 5.191

5.  Periodic health examination, 1996 update: 2. Screening for chlamydial infections. Canadian Task Force on the Periodic Health Examination.

Authors:  H D Davies; E E Wang
Journal:  CMAJ       Date:  1996-06-01       Impact factor: 8.262

6.  In vitro and in vivo activities of sparfloxacin, other quinolones, and tetracyclines against Chlamydia trachomatis.

Authors:  K Nakata; H Maeda; A Fujii; S Arakawa; K Umezu; S Kamidono
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.